Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Endocrine and Neuroendocrine Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT03686124
What this trial is testing

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Who this might be right for
Refractory CancerRecurrent CancerSolid Tumor, Adult+1 more
Immatics US, Inc. 375
Testing effectiveness (Phase 2)Looking for participantsNCT07492680
What this trial is testing

BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Who this might be right for
Solid Tumors
Bristol-Myers Squibb 260
Early research (Phase 1)Study completedNCT00004074
What this trial is testing

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Who this might be right for
Advanced Adult Primary Liver CancerAnaplastic Thyroid CancerBone Metastases+124 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Ended earlyNCT05012397
What this trial is testing

Milademetan in Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorsHead and Neck CarcinomaCholangiocarcinoma+15 more
Rain Oncology Inc 40
Not applicableUnknownNCT05907824
What this trial is testing

Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm

Who this might be right for
Non Functioning Pancreatic Endocrine Tumor
Fudan University 800
Not applicableUnknownNCT05223218
What this trial is testing

Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study

Who this might be right for
Breast CancerOvarian CancerPancreatic Cancer+2 more
Namida Lab 500
Testing effectiveness (Phase 2)UnknownNCT00553683
What this trial is testing

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

Who this might be right for
Breast CancerColorectal CancerGastric Cancer+5 more
Rutgers, The State University of New Jersey 50
Early research (Phase 1)Temporarily pausedNCT03970382
What this trial is testing

Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Who this might be right for
Solid Tumor
PACT Pharma, Inc. 21
Not applicableLooking for participantsNCT05334069
What this trial is testing

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAnn Arbor Stage I Lymphoma+59 more
Alliance for Clinical Trials in Oncology 2,000
Early research (Phase 1)Study completedNCT04148937
What this trial is testing

The CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Who this might be right for
Advanced Cancer
Eli Lilly and Company 52
Testing effectiveness (Phase 2)Ended earlyNCT04985604
What this trial is testing

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorCRAF Gene Amplification+20 more
Day One Biopharmaceuticals, Inc. 23
Testing effectiveness (Phase 2)Study completedNCT02923349
What this trial is testing

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced MalignanciesMetastatic Cancer
Incyte Biosciences International Sàrl 87
Not applicableLooking for participantsNCT04520932
What this trial is testing

Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumor of Pancreas (Disorder)Neuroendocrine Tumor Grade 1
Institut Paoli-Calmettes 82
Not applicableWithdrawnNCT04985357
What this trial is testing

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Who this might be right for
Stage III Breast CancerStage IV Breast CancerStage III Lung Cancer+35 more
Travera Inc
Testing effectiveness (Phase 2)Study completedNCT01845675
What this trial is testing

Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor

Who this might be right for
Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
Peking Union Medical College Hospital 14
Not applicableLooking for participantsNCT01601171
What this trial is testing

Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate

Who this might be right for
Kallmann SyndromeHypogonadotropic HypogonadismHypothalamic Amenorrhea+5 more
Centre Hospitalier Universitaire Vaudois 2,000
Not applicableLooking for participantsNCT05059444
What this trial is testing

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Who this might be right for
Bladder CarcinomaUreter CarcinomaRenal Pelvis Carcinoma+14 more
Guardant Health, Inc. 2,285
Early research (Phase 1)Study completedNCT00496860
What this trial is testing

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Who this might be right for
Progressive Metastatic Malignancies
Altor BioScience 26
Early research (Phase 1)Ended earlyNCT02607813
What this trial is testing

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Who this might be right for
NSCLCOvarian CancerMelanoma+1 more
Novartis Pharmaceuticals 142
Testing effectiveness (Phase 2)Study completedNCT01396382
What this trial is testing

68Ga-DOTATATE PET Scan in Neuroendocrine Cancer

Who this might be right for
Neuroendocrine Carcinoma
Vanderbilt-Ingram Cancer Center 97
Next Page